Orexo, inVentiv Health partner for commercialization of Zubsolv in US
Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence. The drug should be used as part of a comprehensive treatment plan,